痰热清注射液对慢性髓系白血病K562细胞增殖的抑制作用  

Inhibitory effect of Tanreqing injection on proliferation of chronic myelogenous leukemia K562 cell line

作　　者：党艳辉[1,2,3] 李薇[2] 杨波[1] 卢学春[1] 黄玉[1,2,3] 张峰[3] 朱宏丽[1] 

机构地区：[1]解放军总医院南楼血液科,北京100853 [2]吉林大学第一医院血液肿瘤中心,长春130021 [3]中国科学院北京基因组研究所,北京100029

出　　处：《军医进修学院学报》2010年第5期497-499,共3页Academic Journal of Pla Postgraduate Medical School

基　　金：军队"十一.五"基金项目(2007增补)~~

摘　　要：目的观察痰热清注射液对慢性髓系白血病K562细胞增殖的抑制作用。方法将痰热清注射液倍比稀释成1:2、1:4、1:8、1:16、1:32、1:64、1:128、1:256、1:512共9个浓度组,分别处理增殖期慢性髓系白血病K562细胞,镜下观察不同时间点各浓度组细胞生长情况,应用CCK-8法检测细胞增殖能力,绘制生长曲线,计算抑制率和半数抑制浓度(IC50)。结果痰热清注射液能明显抑制K562细胞增殖,细胞倍增时间为24h,1:2至1:8稀释浓度组的细胞毒性大,细胞基本死亡;抑制作用呈剂量和时间依赖性,IC50约为1:55稀释浓度。结论痰热清注射液对K562细胞具有抑制作用,这为临床应用痰热清注射液治疗血液肿瘤并发感染提供了实验基础。Objective To investigate the inhibitory effects of Tanreqing（phlegm and heat clearing） injection on proliferation of chronic myelogenous leukemia K562 cell line.Methods Tanreqing injection was diluted to 9 groups at the concentration of 1：2,1：4,1：8,1：16,1：32,1：64,1：128,1：256 and 1：512,respectively.Proliferating chronic myelogenous leukemia K562 cells were treated with Tanreqing injection at different dilution concentrations and their growth was observed at different time points under a microscope.CCK-8 assay was employed to detect the ability of the cells to proliferate and growth curves were plotted for calculating the inhibition ratio and 50% inhibiting concentration（IC50） of Tanreqing.Results Tanreqing injection could significantly inhibit the proliferation of K562 cells.The proliferating time of the cells was 24h.The cytotoxicity of Tanreqing injection was greater in 1：2,1：4 and 1：8 concentration groups with almost all the cells died.Tanreqing injection inhibited the proliferation of K562 cells in a time-and dose-dependent manner and its IC50 was approximately 1：55 dilution concentration.Conclusion Tanreqing injection can inhibit the proliferation of K562 cells,thus laying a foundation for its use in treatment of hematological malignancies complicated by infection.

关 键 词：痰热清注射液 白血病 髓样 慢性期 K562细胞 细胞增殖 

分 类 号：R73-36[医药卫生—肿瘤]